Abstract
Ovarian carcinoma is the most lethal of the gynecological malignancies. This cancer is characterized by a high frequency of peritoneal dissemination resulting in significant morbidity and mortality, a situation unlike many other cancers. Together with resistance to chemotherapy, this locoregional peritoneal dissemination appears to be the major challenge and obstacle to improving outcomes in ovarian cancer. Relatively little scientific effort has been invested in making significant progress in the latter; therefore, developing a sound understanding of the molecular events underlying that process would be helpful. The focus of this review is to discuss the research that has been undertaken preclinically and clinically to conceptually develop the principles of, understand and target locoregional peritoneal dissemination in ovarian cancer.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.